Alimera Sciences Revenue and Competitors

Atlanta, GA USA

Location

$304.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Alimera Sciences's estimated annual revenue is currently $300M per year.(i)
  • Alimera Sciences's estimated revenue per employee is $677,201
  • Alimera Sciences's total funding is $304.4M.

Employee Data

  • Alimera Sciences has 443 Employees.(i)
  • Alimera Sciences grew their employee count by 1% last year.

Alimera Sciences's People

NameTitleEmail/Phone
1
Sr. VPReveal Email/Phone
2
VP, Managed MarketsReveal Email/Phone
3
VP, Human CapitalReveal Email/Phone
4
VP Global Marketing/Head Commercial ExcellenceReveal Email/Phone
5
VP SalesReveal Email/Phone
6
VP, Thought Leader Engagement at Alimera SciencesReveal Email/Phone
7
VP, General CounselReveal Email/Phone
8
VP & General CounselReveal Email/Phone
9
Co-Founder, Chief Marketing Officer, SVP Corporate Communications and Managed MarketsReveal Email/Phone
10
CEO, President & DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.5M1228%N/AN/A
#2
$10.7M53-17%N/AN/A
#3
$9.2M462%N/AN/A
#4
$24.1M1205%N/AN/A
#5
$7.2M36-20%N/AN/A
#6
$27.7M138-30%N/AN/A
#7
$39.8M19837%N/AN/A
#8
$0.5M525%$50MN/A
#9
$13.7M68-7%N/AN/A
#10
$10.3M5111%N/AN/A
Add Company

What Is Alimera Sciences?

Alimera Sciences will become a leading specialty ophthalmic pharmaceutical company by delivering intelligent products for the eye care provider and consumer. We will always consider what is right for our customers, partners, shareholders and employees in our decisions. Alimera Sciences will achieve its mission because the company is dedicated to being \"ophthalmic intelligent.\" The management team has built a reputation for decisiveness, speed to market, and integrity with over 100-plus years of collective ophthalmic experience

keywords:N/A

$304.4M

Total Funding

443

Number of Employees

$300M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alimera Sciences News

2022-04-19 - Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts ...

HC Wainwright dropped their price objective on shares of Alimera Sciences from $12.00 to $10.00 and set a “buy” rating on the stock in a report...

2022-04-13 - Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by ...

Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at StockNews.com. Posted by admin on Apr 12th, 2022.

2022-04-06 - Alimera Exhibits Continued Growth and Expansion With New ...

ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission...

2021-04-14 - Alimera Sciences, Inc. announced that it has received $10 million in funding from Ocumension Therapeutics

Alimera Sciences, Inc. (NasdaqGM:ALIM) announced that it has entered into a share purchase agreement for a private placement of 1,144,945 common shares, par value $0.01 per share, at a purchase price of $8.734044 per share for gross proceeds of $10,000,000 on April 14, 2021. The transaction incl ...

2021-04-14 - ALIMERA SCIENCES, INC. Alimera Sciences : Receives $20 Million From Ocumension Therapeutics

Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments Ocumension makes a $10 million equity investment in Alimera ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alim ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$69M4532%N/A
#2
$83M45810%N/A
#3
$81.4M4655%N/A
#4
$77.4M476-10%N/A
#5
$163.4M4841%N/A